ESR1 and breast carcinoma: In contrast to HIF-1α, Spalt-like transcription factor 2 (SALL2), a transcription factor related to disease progression, enhances the sensitivity of breast cancer cells to tamoxifen, while ERα is downregulated after silencing SALL2 (Ye et al., 2019).